Author

Tetsuhi Inada

OpenAlex ID: A5017101640

A phase I first-in-human study of PRI-724 in patients (pts) with advanced solid tumors.

2013 · Anthony B. El-Khoueiry, Yan Ning, et al. · Journal of Clinical Oncology · 121

Final results of a phase Ib dose-escalation study of PRI-724, a CBP/beta-catenin modulator, plus gemcitabine (GEM) in patients with advanced pancreatic adenocarcinoma (APC) as second-line therapy after FOLFIRINOX or FOLFOX.

2016 · Andrew H. Ko, E. Gabriela Chiorean, et al. · Journal of Clinical Oncology · 69

A phase Ib dose-escalation study of PRI-724, a CBP/beta-catenin modulator, plus gemcitabine (GEM) in patients with advanced pancreatic adenocarcinoma (APC) as second-line therapy after FOLFIRINOX or FOLFOX.

2015 · Robert R. McWilliams, Andrew H. Ko, et al. · Journal of Clinical Oncology · 44

Works count: 3

Citation count: 234

H-index: 3

I10-index: 3